Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million
Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

April 16, 2024 M&A

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson, Adrian Filipovic and Karin Karsten.

Related

Vinge advises Bergs Timber on the sale of Vika Woods to HS Timber group

 Vinge has advised Bergs Timber AB on the sale of the Latvian wood processing company Vika Woods SIA to the Austrian HS Timber group.
January 10, 2025

Vinge has advised Stenhus Fastigheter i Norden AB in connection with their uplisting to Nasdaq Stockholm

 Vinge has advised Stenhus Fastigheter i Norden AB (publ) (“Stenhus Fastigheter” or the “Company”) in connection with the Company's uplisting to Nasdaq Stockholm. The first day of trading on Nasdaq Stockholm was 18 December 2024.
December 20, 2024

Vinge advised Platzer on its sale of building rights in Södra Änggården to the property developer Bonava

 The transaction is being carried out through a company acquisition at an underlying property value of SEK 186 million.
December 20, 2024